Rodman & Renshaw Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Analysts at Rodman & Renshaw initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $17.00 price target on the stock.

Other equities analysts have also issued reports about the stock. BTIG Research reduced their target price on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Evercore ISI cut their target price on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, September 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities lowered their target price on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a report on Monday, September 22nd. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.88.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR traded up $0.07 during trading hours on Tuesday, reaching $1.55. The stock had a trading volume of 280,475 shares, compared to its average volume of 1,559,176. The stock has a market capitalization of $43.23 million, a PE ratio of -0.26 and a beta of 3.07. Jasper Therapeutics has a 52 week low of $1.39 and a 52 week high of $7.19. The company has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $2.54.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.12). Equities research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JSPR. Acadian Asset Management LLC acquired a new position in Jasper Therapeutics during the 1st quarter worth about $46,000. Marex Group plc acquired a new position in Jasper Therapeutics during the 2nd quarter worth approximately $74,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at approximately $78,000. Voleon Capital Management LP acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at $50,000. Finally, Goldman Sachs Group Inc. lifted its position in shares of Jasper Therapeutics by 11.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after purchasing an additional 23,453 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.